Innoviva to acquire La Jolla Pharma for $149M including debt

Jul. 11, 2022 7:46 AM ETInnoviva, Inc. (INVA)INVABy: Dulan Lokuwithana, SA News Editor8 Comments

word m and a made with wood building blocks, stock image

Maks_Lab/iStock via Getty Images

  • Innoviva, Inc. (INVA), a diversified holding company, has agreed to acquire the commercial-stage biotech La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $6.23 per share in cash, implying an enterprise value of ~$149M, the companies announced on Monday.
  • Per the terms of the merger agreement, Innoviva (INVA) intends to pay $5.95 per share for La Jolla (LJPC) and $0.28 per share for additional cash proceeds from the divestiture of a non-core asset.
  • The initial purchase price of $5.95 indicates a premium of 70% to the 30-day volume-weighted average price (VWAP).
  • Innoviva (INVA), through one of its subsidiaries, will start a tender offer in this regard on or before July 25, 2022. The deal is expected to close within 30 business days.
  • In 2017, the FDA approved La Jolla’s (LJPC) lead product to increase blood pressure in adults with septic or other distributive shock. A year later, the agency greenlighted its second product XERAVA as a treatment for adults with complicated intra-abdominal infections.
  • The company reported $43.5M of net product sales in 2021 with ~30% YoY growth.

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.